https://www.pharmaradar360.com/article/a-new-kind-of-hiv-pill-just-passed-its-first-test-in-humans-09e2921a97f76f27Pharma Surgeen2026-07-31T10:02:30.000ZA New Kind of HIV Pill Just Passed Its First Test in Humanshttps://www.pharmaradar360.com/article/the-national-gonorrhoea-vaccination-programme-using-4cmenb-vaccine-frequently-as-479b1a7456a61302Pharma Surgeen2026-07-31T09:44:52.000ZThe national gonorrhoea vaccination programme using 4CMenB vaccine: frequently asked questionshttps://www.pharmaradar360.com/article/european-drug-manufacturers-under-threat-from-proposed-us-supply-chain-bill-83c2d26863857af7Pharma Surgeen2026-07-31T09:36:09.000ZEuropean drug manufacturers under threat from proposed US supply chain billhttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-mhra-phase-i-accreditation-scheme-0a6f6f31a937b2b5Pharma Surgeen2026-07-31T09:31:24.000ZClinical trials for medicines: MHRA phase I accreditation schemehttps://www.pharmaradar360.com/article/cell-and-gene-therapy-manufacturers-turn-to-specialist-automation-partners-19344ef2e745035aPharma Surgeen2026-07-31T09:20:25.000ZCell and gene therapy manufacturers turn to specialist automation partnershttps://www.pharmaradar360.com/article/india-s-sun-pharma-posts-higher-quarterly-profit-on-strong-demand-a6c59eda54ada6a6Pharma Surgeen2026-07-31T09:09:46.000ZIndia's Sun Pharma posts higher quarterly profit on strong demandhttps://www.pharmaradar360.com/article/measures-from-the-adult-social-care-outcomes-framework-england-2025-to-2026-8bead6d4b132e9c4Pharma Surgeen2026-07-31T09:04:06.000ZMeasures from the adult social care outcomes framework, England: 2025 to 2026https://www.pharmaradar360.com/article/safeguarding-adults-england-2025-to-2026-report-5a1fde56716d266cPharma Surgeen2026-07-31T09:00:50.000ZSafeguarding adults, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/deferred-payment-agreements-england-2025-to-2026-report-2caf38b8e49cf146Pharma Surgeen2026-07-31T08:58:04.000ZDeferred payment agreements, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/adult-social-care-survey-england-2025-to-2026-report-9053469da7332a96Pharma Surgeen2026-07-31T08:49:13.000ZAdult social care survey, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/healthy-child-programme-8d6d3d976dfbbf4fPharma Surgeen2026-07-31T08:30:07.000ZHealthy child programmehttps://www.pharmaradar360.com/article/care-continuity-between-midwifery-and-health-visiting-services-7052bd945725089cPharma Surgeen2026-07-31T08:30:04.000ZCare continuity between midwifery and health visiting serviceshttps://www.pharmaradar360.com/article/fda-regulatory-hurdles-expose-rare-disease-drug-crisis-b970ef9d24148159Pharma Surgeen2026-07-31T08:30:00.000ZFDA Regulatory Hurdles Expose Rare Disease Drug Crisishttps://www.pharmaradar360.com/article/unlocking-the-east-of-england-s-life-sciences-potential-reflections-from-our-reg-5210f7af0795e268Pharma Surgeen2026-07-31T08:29:55.000ZUnlocking the East of England’s life sciences potential: Reflections from our regional roundtablehttps://www.pharmaradar360.com/article/kosdaq-shift-to-ai-and-chips-hits-ingenia-therapeutics-ipo-demand-chosunbiz-780eca151a03e9ddPharma Surgeen2026-07-31T08:28:00.000ZKOSDAQ shift to AI and chips hits Ingenia Therapeutics IPO demand - CHOSUNBIZhttps://www.pharmaradar360.com/article/dhsc-spending-over-500-9d0eec9bf491adbdPharma Surgeen2026-07-31T08:23:03.000ZDHSC spending over £500https://www.pharmaradar360.com/article/dhsc-spending-over-500-june-2026-6a9f886019dc866cPharma Surgeen2026-07-31T08:22:59.000ZDHSC: spending over £500, June 2026https://www.pharmaradar360.com/article/dimensional-fund-advisors-lp-purchases-73-410-shares-of-teva-pharmaceutical-indu-51ad3d1262ce51caPharma Surgeen2026-07-31T08:13:52.000ZDimensional Fund Advisors LP Purchases 73,410 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ono-pharmaceutical-profit-rose-despite-revenue-decline-driven-by-cost-cuts-and-o-f66830dc014a1c31Pharma Surgeen2026-07-31T08:09:44.000ZOno Pharmaceutical : Profit rose despite revenue decline, driven by cost cuts and overseas sales growthhttps://www.pharmaradar360.com/article/apnimed-s-ipo-dream-comes-true-with-upsized-192m-ipo-to-fund-sleep-apnea-pill-la-ffdc56d726c02f5dPharma Surgeen2026-07-31T08:09:06.000ZApnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchhttps://www.pharmaradar360.com/article/the-ai-ready-factory-how-itot-integration-transforms-pharmaceutical-manufacturin-82aad78a3caff2ccPharma Surgeen2026-07-31T08:03:45.000ZThe AI-Ready Factory How ITOT Integration Transforms Pharmaceutical Manufacturing Data Into Actionable Intelligencehttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-shares-rise-2-03-in-today-s-session-5a04c8b677c45d35Pharma Surgeen2026-07-31T08:01:08.000ZSun Pharmaceutical Industries Shares Rise 2.03% in Today's Sessionhttps://www.pharmaradar360.com/article/mapping-ai-drug-discovery-the-companies-behind-biotech-s-most-searched-technolog-68c00e034de4829bPharma Surgeen2026-07-31T07:59:38.000ZMapping AI Drug Discovery: The Companies Behind Biotech’s Most-Searched Technologyhttps://www.pharmaradar360.com/article/latigo-s-ltg-001-phase-2b-data-signals-a-new-design-standard-for-nav1-8-pain-tri-6fc95c4eef6150a8Pharma Surgeen2026-07-31T07:37:59.000ZLatigo’s LTG-001 Phase 2b Data Signals a New Design Standard for NaV1.8 Pain Trialshttps://www.pharmaradar360.com/article/press-release-on-il-sole-24-ore-interim-report-first-half-as-at-30-june-2026-5308b80c7823e971Pharma Surgeen2026-07-31T07:14:43.000ZPress release (on il Sole 24 Ore) – Interim Report First Half (as at 30 June 2026)https://www.pharmaradar360.com/article/la-aemps-informa-sobre-la-restriccion-de-microplasticos-y-sus-implicaciones-para-33d7a5d38c312557Pharma Surgeen2026-07-31T07:00:28.000ZLa AEMPS informa sobre la restricción de microplásticos y sus implicaciones para los productos biocidas de su competenciahttps://www.pharmaradar360.com/article/prac-juli-2026-nieuwe-veiligheidsaanbevelingen-voor-anticonceptiemiddelen-met-de-67e2ec953abb2b0ePharma Surgeen2026-07-31T06:45:46.000ZPRAC juli 2026: nieuwe veiligheidsaanbevelingen voor anticonceptiemiddelen met desogestrel en etonogestrel en voor Litfulohttps://www.pharmaradar360.com/article/selinexor-phase-3-trial-misses-primary-endpoint-in-endometrial-cancer-a285d71605c0e50fPharma Surgeen2026-07-31T06:43:09.000ZSelinexor Phase 3 Trial Misses Primary Endpoint in Endometrial Cancerhttps://www.pharmaradar360.com/article/eyepoint-completes-enrollment-of-duravyu-phase-3-trials-for-diabetic-macular-ede-018317361d37222bPharma Surgeen2026-07-31T06:38:06.000ZEyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edemahttps://www.pharmaradar360.com/article/fda-agrees-single-phase-3-trial-sufficient-for-ath434-msa-approval-path-35014be2eac3110fPharma Surgeen2026-07-31T06:38:04.000ZFDA Agrees Single Phase 3 Trial Sufficient for ATH434 MSA Approval Pathhttps://www.pharmaradar360.com/article/mog-f8b87d67e31f27f3Pharma Surgeen2026-07-31T06:30:00.000Zエンスプリング、国内初の「MOG抗体関連疾患の再発予防」治療薬として適応拡大申請https://www.pharmaradar360.com/article/chugai-files-for-additional-indication-of-enspryng-as-japan-rsquo-s-potential-fi-8fb5f2c6035da10fPharma Surgeen2026-07-31T06:30:00.000ZChugai Files for Additional Indication of Enspryng as Japan’s Potential First Treatment for Prevention of Relapse in MOG Antibody-associated Diseasehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-stock-12-month-price-target-raised-to-19-4-eadb5dfe895ac37bPharma Surgeen2026-07-31T06:20:00.000ZTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.43, Implies 13% Upsidehttps://www.pharmaradar360.com/article/pfizer-seeks-label-expansion-for-litfulo-after-double-phase-iii-nsv-win-41a1049905c13ad9Pharma Surgeen2026-07-31T06:00:00.000ZPfizer seeks label expansion for Litfulo after double Phase III NSV winhttps://www.pharmaradar360.com/article/the-supreme-court-confirmed-the-ruling-that-cha-biotech-which-caused-the-stock-p-08b9850c0f54c50cPharma Surgeen2026-07-31T05:39:30.000ZThe Supreme Court confirmed the ruling that Cha Biotech, which caused the stock price crash by discl..https://www.pharmaradar360.com/article/teva-teva-stock-faces-earnings-shock-despite-strong-brand-growth-45eea88ab468e7efPharma Surgeen2026-07-31T05:37:39.000ZTeva (TEVA) Stock Faces Earnings Shock Despite Strong Brand Growthhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-maintained-at-neutral-by-major-u-s-securities-firm-target-cb3282f7773a0374Pharma Surgeen2026-07-31T05:35:00.000ZTakeda Pharmaceutical Maintained at "Neutral" by Major U.S. Securities Firm, Target Price Raised to ¥5,800https://www.pharmaradar360.com/article/mid-day-exclusive-citizens-must-demand-standardised-food-inside-tukaram-mundhe-s-c6cdd620161a56bdPharma Surgeen2026-07-31T05:32:00.000ZMid-Day Exclusive | 'Citizens must demand standardised food': Inside Tukaram Mundhe's food safety crackdownhttps://www.pharmaradar360.com/article/new-certification-criteria-reshape-race-for-korea-s-innovative-pharma-company-ti-6362d5a33533bffdPharma Surgeen2026-07-31T05:12:00.000ZNew certification criteria reshape race for Korea’s 'innovative pharma company' titlehttps://www.pharmaradar360.com/article/egypt-highlights-health-reform-gains-calls-for-stronger-global-cooperation-again-894c79198b4f4807Pharma Surgeen2026-07-31T05:07:00.000ZEgypt highlights health reform gains, calls for stronger global cooperation against rising health threatshttps://www.pharmaradar360.com/article/fda-inspects-bombay-high-court-canteens-4103c7b8eca41614Pharma Surgeen2026-07-31T04:22:00.000ZFDA inspects Bombay High Court canteenshttps://www.pharmaradar360.com/article/cen-biotech-inc-revenue-breakdown-otc-cenbf-b80b7229ba8df14aPharma Surgeen2026-07-31T04:20:25.000ZCen Biotech, Inc. Revenue Breakdown – OTC:CENBFhttps://www.pharmaradar360.com/article/quality-affordability-and-innovation-define-india-s-pharma-success-pharmexcil-ch-5800a4de0bb35158Pharma Surgeen2026-07-31T04:10:19.000ZQuality, affordability and innovation define India's pharma success: PHARMEXCIL Chairman Namit Joshihttps://www.pharmaradar360.com/article/who-unveils-global-framework-to-accelerate-greener-pharmaceutical-regulation-7d239890c6769fe0Pharma Surgeen2026-07-31T04:05:42.000ZWHO Unveils Global Framework To Accelerate Greener Pharmaceutical Regulationhttps://www.pharmaradar360.com/article/we-re-in-india-have-to-take-realistic-approach-bombay-hc-restores-fda-suspended-92c7b7e62adc06d9Pharma Surgeen2026-07-31T04:01:45.000Z“We’re in India, Have to Take Realistic Approach”: Bombay HC Restores FDA-Suspended License of Navi Mumbai’s Park Inn by Radisson, Says Insects in Kitchen Can't Shut Down 4-Star Hotelhttps://www.pharmaradar360.com/article/ono-pharmaceutical-core-profit-rose-despite-lower-revenue-driven-by-royalties-an-0dab2491a6464469Pharma Surgeen2026-07-31T03:02:00.000ZOno Pharmaceutical : Core profit rose despite lower revenue, driven by royalties and overseas growthhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-misight-1-day-bdaa9059666c384aPharma Surgeen2026-07-31T03:00:00.000Z[SHINSA]English Translation of Review Report: MiSight 1 Dayhttps://www.pharmaradar360.com/article/mumbai-latest-news-today-on-july-31st-2026-bhiwandi-collapse-fda-crackdown-drug-4efa6d67f2934cdfPharma Surgeen2026-07-31T02:51:15.000ZMumbai Latest News Today on July 31st, 2026: Bhiwandi Collapse, FDA Crackdown & Drug-Free Campaignhttps://www.pharmaradar360.com/article/legend-biotech-legn-ceo-exit-raises-questions-is-the-stock-still-cheap-19701e8a113b3507Pharma Surgeen2026-07-31T02:37:30.000ZLegend Biotech (LEGN) CEO Exit Raises Questions, Is The Stock Still Cheap?https://www.pharmaradar360.com/article/stocks-in-focus-takeda-pharmaceutical-declined-weighed-down-by-its-earnings-repo-d298f557926fc04fPharma Surgeen2026-07-31T02:29:47.000Z[Stocks in Focus] Takeda Pharmaceutical declined, weighed down by its earnings report; some analysts noted that it was 'left out of the spotlight' amid rising interest in AI-related stocks.https://www.pharmaradar360.com/article/shionogi-backed-biotech-apnimed-raises-192-million-in-us-ipo-a452df1f3acec29fPharma Surgeen2026-07-31T02:24:00.000ZShionogi-Backed Biotech Apnimed Raises $192 Million in US IPOhttps://www.pharmaradar360.com/article/fda-approves-first-oral-pcsk9-inhibitor-for-adults-with-high-cholesterol-2283722b5136d319Pharma Surgeen2026-07-31T02:15:00.000ZFDA approves first oral PCSK9 inhibitor for adults with high cholesterolhttps://www.pharmaradar360.com/article/after-celltrion-taisho-joins-kaigen-signs-japan-license-deal-for-fcrn-therapy-26213f699e02305aPharma Surgeen2026-07-31T02:12:19.000ZAfter Celltrion, Taisho Joins: Kaigen Signs Japan License Deal for FcRn Therapyhttps://www.pharmaradar360.com/article/us-tariffs-pose-threat-to-india-s-pharma-sector-f8ce9c78a3dfec7fPharma Surgeen2026-07-31T02:10:39.000ZUS tariffs pose threat to India's pharma sectorhttps://www.pharmaradar360.com/article/radiopharm-theranostics-advances-rad-101-toward-phase-3-after-strong-trial-resul-668b40054859b32ePharma Surgeen2026-07-31T01:48:20.000ZRadiopharm Theranostics Advances RAD 101 Toward Phase 3 After Strong Trial Resultshttps://www.pharmaradar360.com/article/biotech-growth-trust-plc-revenue-breakdown-aquisuk-biogl-8ec0c28aec1981bePharma Surgeen2026-07-31T01:02:42.000ZBiotech Growth Trust PLC Revenue Breakdown – AQUISUK:BIOGLhttps://www.pharmaradar360.com/article/kaigene-enters-into-exclusive-licensing-agreement-with-taisho-pharmaceutical-for-b3e2c6f4886e2455Pharma Surgeen2026-07-31T01:02:12.000ZKaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japanhttps://www.pharmaradar360.com/article/kaigene-enters-into-exclusive-licensing-agreement-with-taisho-pharmaceutical-for-6c9e7058dbc694a9Pharma Surgeen2026-07-31T01:01:00.000ZKaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japanhttps://www.pharmaradar360.com/article/hanmi-pyeongtaek-plant-secures-top-safety-grade-again-bolstering-korea-drug-outp-cfbc4a12d26ec355Pharma Surgeen2026-07-31T00:39:00.000ZHanmi Pyeongtaek plant secures top safety grade again, bolstering Korea drug output - CHOSUNBIZhttps://www.pharmaradar360.com/article/three-s-an-ipo-crowd-biotech-trio-set-to-raise-575m-in-total-c74733d740d527afPharma Surgeen2026-07-31T00:11:36.000ZThree's an IPO crowd: biotech trio set to raise $575M in totalhttps://www.pharmaradar360.com/article/kpti-looks-18-2-overvalued-on-gf-valuetm-after-phase-3-trial-set-061fe27f53252254Pharma Surgeen2026-07-31T00:08:14.000ZKPTI Looks 18.2% Overvalued on GF Value™ After Phase 3 Trial Sethttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-3c395c9e358285cbPharma Surgeen2026-07-31T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-b4d5895a01e246f3Pharma Surgeen2026-07-31T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-11155bd03648139fPharma Surgeen2026-07-31T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-d8b3190f9c337cd2Pharma Surgeen2026-07-31T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-13423e8b711e9c15Pharma Surgeen2026-07-31T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-bc7d251a592191b7Pharma Surgeen2026-07-31T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-7a111ec7b035d9d5Pharma Surgeen2026-07-31T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-4dd00df478664b27Pharma Surgeen2026-07-31T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-71c89adfc6e83408Pharma Surgeen2026-07-31T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-333a8b5d061f0604Pharma Surgeen2026-07-31T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5323b6eadda0a1bbPharma Surgeen2026-07-31T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-01a3891e6e1ad3a1Pharma Surgeen2026-07-31T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-5662f346ca27e51bPharma Surgeen2026-07-31T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-c495d8069c88431ePharma Surgeen2026-07-31T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicare-program-fy-2027-inpatient-psychiatric-facilities-prospective-payment-sy-8950715721a572b0Pharma Surgeen2026-07-31T00:00:00.000ZMedicare Program; FY 2027 Inpatient Psychiatric Facilities Prospective Payment System-Rate Updatehttps://www.pharmaradar360.com/article/reducing-bureaucracy-and-burden-for-family-assistance-programs-708ce48d8a8f5576Pharma Surgeen2026-07-31T00:00:00.000ZReducing Bureaucracy and Burden for Family Assistance Programshttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-data-use-certification-for-the-nih-br-4723a27aa281ac65Pharma Surgeen2026-07-31T00:00:00.000ZProposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)https://www.pharmaradar360.com/article/medicare-program-prospective-payment-system-and-consolidated-billing-for-skilled-cfeb0d49ed2b43bcPharma Surgeen2026-07-31T00:00:00.000ZMedicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 2027https://www.pharmaradar360.com/article/national-center-for-complementary-and-integrative-health-amended-notice-of-meeti-d1def6219c9f646dPharma Surgeen2026-07-31T00:00:00.000ZNational Center for Complementary and Integrative Health; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-cb28c7535db85db0Pharma Surgeen2026-07-31T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-69da69980676912dPharma Surgeen2026-07-31T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-46a7e6261d9ead5cPharma Surgeen2026-07-31T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/office-of-the-secretary-notice-of-meeting-b5e8830e611f6667Pharma Surgeen2026-07-31T00:00:00.000ZOffice of the Secretary; Notice of Meetinghttps://www.pharmaradar360.com/article/drug-label-update-sugammadex-588214b5a2f10737Pharma Surgeen2026-07-31T00:00:00.000ZDrug label update: Sugammadexhttps://www.pharmaradar360.com/article/drug-label-update-dehydrated-alcohol-4de2a9d54f6767d5Pharma Surgeen2026-07-31T00:00:00.000ZDrug label update: Dehydrated Alcoholhttps://www.pharmaradar360.com/article/pharmacologic-treatment-response-in-panic-disorder-with-comorbid-medical-conditi-f6b2eedc667a4939Pharma Surgeen2026-07-31T00:00:00.000ZPharmacologic Treatment Response in Panic Disorder with Comorbid Medical Conditions: A Systematic and Narrative Reviewhttps://www.pharmaradar360.com/article/feasibility-study-of-a-novel-mhealth-clinical-decision-support-application-to-en-8b5b7211ab3e0fa3Pharma Surgeen2026-07-31T00:00:00.000ZFeasibility study of a novel mHealth clinical decision support application to enable community health workers to manage hypertension in rural Guatemalahttps://www.pharmaradar360.com/article/socio-demographic-and-clinical-profile-of-autism-spectrum-disorder-in-children-a-c203e65c7b8052e4Pharma Surgeen2026-07-31T00:00:00.000ZSocio-Demographic and Clinical Profile of Autism Spectrum Disorder in Children Attending a Tertiary Care Hospital: A Study of 100 Caseshttps://www.pharmaradar360.com/article/microfluidic-t-chip-enables-one-step-clinical-scale-t-cell-purification-from-blo-0f5085ef6dbfaf1aPharma Surgeen2026-07-31T00:00:00.000ZMicrofluidic T-Chip enables one-step clinical-scale T-cell purification from blood products for CAR T-cell manufacturinghttps://www.pharmaradar360.com/article/bruylant-s-test-for-2-2-bimorphine-020e738d32f016efPharma Surgeen2026-07-31T00:00:00.000ZBruylant’s test for 2,2’-bimorphinehttps://www.pharmaradar360.com/article/synthesis-characterization-and-antibacterial-activity-of-benzimidazole-schiff-ba-64bd8a674dc96a12Pharma Surgeen2026-07-31T00:00:00.000ZSynthesis, characterization, and antibacterial activity of Benzimidazole Schiff Bases and Bis(thiazolidin-4-one) Derivativeshttps://www.pharmaradar360.com/article/synthesis-characterization-and-antioxidant-activity-of-pt-ii-and-pd-ii-dithiocar-aeeb5f082c881e2dPharma Surgeen2026-07-31T00:00:00.000ZSynthesis, Characterization, and Antioxidant Activity of Pt (II) and Pd (II) Dithiocarbamate Complexes Derived from 4-Methyl-2-phenylpiperazine and 4-Phenylpiperazine with and without 1,2-Bis(diphenylphosphino)ethanehttps://www.pharmaradar360.com/article/reconstruction-of-distal-amputation-of-the-right-index-finger-using-a-kutler-fla-3aa51ebd5b266fdbPharma Surgeen2026-07-31T00:00:00.000ZReconstruction of Distal Amputation of the Right Index Finger Using a Kutler Flap: A Case Reporthttps://www.pharmaradar360.com/article/gallstone-ileus-caused-by-a-cholecystoduodenal-fistula-in-a-58-year-old-man-a-ca-dd36fc84b4605c06Pharma Surgeen2026-07-31T00:00:00.000ZGallstone Ileus Caused by A Cholecystoduodenal Fistula in A 58-Year-Old Man: A Case Reporthttps://www.pharmaradar360.com/article/incidental-perioperative-detection-of-congenital-methemoglobinemia-a-prospective-65fcd64397ff3896Pharma Surgeen2026-07-31T00:00:00.000ZIncidental perioperative detection of congenital methemoglobinemia: A prospective case series from a South Indian referral centrehttps://www.pharmaradar360.com/article/beyond-infections-clinical-and-genetic-spectrum-of-pediatric-immune-dysregulatio-c2dd7c04d28cd178Pharma Surgeen2026-07-31T00:00:00.000ZBeyond Infections: Clinical and Genetic Spectrum of Pediatric Immune Dysregulation Disordershttps://www.pharmaradar360.com/article/intracameral-steroids-in-pediatric-cataract-surgery-clinical-insights-and-the-ro-d578ee729b069e5bPharma Surgeen2026-07-31T00:00:00.000ZIntracameral steroids in pediatric cataract surgery: Clinical insights and the road ahead for sustained drug deliveryhttps://www.pharmaradar360.com/article/clinical-profile-and-perioperative-risk-factors-for-post-cataract-surgery-nonart-dd9bd3cb6a90ec1bPharma Surgeen2026-07-31T00:00:00.000ZClinical profile and perioperative risk factors for post-cataract surgery nonarteritic anterior ischemic optic neuropathy in an Indian population: An emulated target trialhttps://www.pharmaradar360.com/article/reevaluating-heart-transplant-compatibility-a-retrospective-analysis-using-echoc-796843a4b7526a0bPharma Surgeen2026-07-31T00:00:00.000ZReevaluating Heart Transplant Compatibility: A Retrospective Analysis Using Echocardiographic Left Ventricular Mass Matchinghttps://www.pharmaradar360.com/article/retroperitoneal-renal-surgery-with-the-hugotm-ras-system-feasibility-setting-and-ba798b494fda94d8Pharma Surgeen2026-07-31T00:00:00.000ZRetroperitoneal Renal Surgery with the Hugo™ RAS System: Feasibility, Setting and Perioperative Outcomes of the First Dedicated Serieshttps://www.pharmaradar360.com/article/machine-learning-based-prediction-of-cervical-pedicle-screw-malposition-from-cli-71724bc124c90b56Pharma Surgeen2026-07-31T00:00:00.000ZMachine-Learning-Based Prediction of Cervical Pedicle Screw Malposition from Clinical and Anatomical Featureshttps://www.pharmaradar360.com/article/autologous-cutis-and-subcutis-micrografts-combined-with-a-collagen-elastin-derma-5c706009001b232cPharma Surgeen2026-07-31T00:00:00.000ZAutologous cutis and subcutis micrografts combined with a collagen–elastin dermal scaffold for chronic wounds: a retrospective single-arm clinical study with prospectively collected datahttps://www.pharmaradar360.com/article/model-based-clinical-utility-of-pharmacogenetic-testing-and-its-potential-popula-544c28a47bed54dcPharma Surgeen2026-07-31T00:00:00.000ZModel-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwehttps://www.pharmaradar360.com/article/correlation-between-the-cd8-t-cell-ifn-axis-and-clinical-disease-progression-at-5680fde7dd190c7ePharma Surgeen2026-07-31T00:00:00.000ZCorrelation between the CD8+ T cell/IFN-γ axis and clinical disease progression at different phases of ITPhttps://www.pharmaradar360.com/article/prevalence-and-multilevel-factors-associated-with-clinical-breast-examination-up-ea17d984e481572cPharma Surgeen2026-07-31T00:00:00.000ZPrevalence and multilevel factors associated with clinical breast examination uptake among women in sub-Saharan Africa: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/dietary-linolenic-acid-improves-skin-blood-flow-following-cold-exposure-and-endo-3baf769d9e390b91Pharma Surgeen2026-07-31T00:00:00.000ZDietary α-linolenic acid improves skin blood flow following cold exposure and endothelial function in healthy adults: a randomized, double-blind, placebo-controlled, parallel-group comparative trialhttps://www.pharmaradar360.com/article/artificial-intelligence-and-telemedicine-integration-in-managing-in-flight-medic-7ab9292a789fe09ePharma Surgeen2026-07-31T00:00:00.000ZArtificial Intelligence and telemedicine integration in managing in-flight medical emergencies: Current evidence, clinical applications and future directionshttps://www.pharmaradar360.com/article/clinical-and-tomographic-features-of-a-presumed-macular-corneal-dystrophy-in-a-m-7f4bb3ac0ee2480ePharma Surgeen2026-07-31T00:00:00.000ZClinical and tomographic features of a presumed macular corneal dystrophy in a Moroccan sibling cohorthttps://www.pharmaradar360.com/article/the-evolving-profile-of-herpes-zoster-outpatients-a-literature-review-of-socio-d-8d5e8bc161b772b4Pharma Surgeen2026-07-31T00:00:00.000ZThe evolving profile of herpes zoster outpatients: A literature review of socio-demographics, comorbidities, and clinical manifestationshttps://www.pharmaradar360.com/article/clinical-characteristics-and-treatment-response-of-infantile-hemangioma-patients-2c54ff2963790b6ePharma Surgeen2026-07-31T00:00:00.000ZClinical characteristics and treatment response of infantile hemangioma patients treated with oral propranololhttps://www.pharmaradar360.com/article/stratified-analysis-of-socioeconomic-status-hypertension-burden-and-drug-complia-a5cb31c5ef2e5d41Pharma Surgeen2026-07-31T00:00:00.000ZStratified analysis of socioeconomic status, hypertension burden and drug compliance in South-Eastern Nigeriahttps://www.pharmaradar360.com/article/examine-the-impact-of-mesenchymal-stem-cells-on-corneal-healing-via-clinical-and-cd8979e8cfea317cPharma Surgeen2026-07-31T00:00:00.000ZExamine the impact of mesenchymal stem cells on corneal healing via clinical and molecular researchhttps://www.pharmaradar360.com/article/monitoring-the-organic-enrichment-and-the-trophic-status-of-the-aquatic-environm-e9b561567b6a0ef5Pharma Surgeen2026-07-31T00:00:00.000ZMonitoring the organic enrichment and the trophic status of the aquatic environment beneath a long-line system of Mediterranean mussel culturehttps://www.pharmaradar360.com/article/antioxidant-activity-and-quantification-of-phenolic-compounds-in-methanolic-extr-a80f1f5989c6b6acPharma Surgeen2026-07-31T00:00:00.000ZAntioxidant activity and quantification of phenolic compounds in methanolic extract of Origanum majorana L.https://www.pharmaradar360.com/article/quantitative-endocannabinoid-profiling-a-systems-biology-framework-for-natural-m-0c4c550bd35e3e96Pharma Surgeen2026-07-31T00:00:00.000ZQuantitative endocannabinoid profiling: A systems biology framework for natural medicine researchhttps://www.pharmaradar360.com/article/epidemiology-clinical-characteristics-and-outcomes-of-patients-with-severe-traum-a2d4e6606b50b049Pharma Surgeen2026-07-31T00:00:00.000ZEpidemiology, clinical characteristics and outcomes of patients with severe traumatic brain injury treated by emergency medical services in New Zealand: a retrospective observational studyhttps://www.pharmaradar360.com/article/the-evolution-of-the-treadmill-test-in-cardiology-from-clinical-observation-to-a-ae08429d761d6b9ePharma Surgeen2026-07-31T00:00:00.000ZThe evolution of the treadmill test in cardiology: from clinical observation to a global standard of functional diagnosticshttps://www.pharmaradar360.com/article/therapeutic-potential-of-talahridaya-marma-in-cardiovascular-homeostasis-a-clini-2a96b835ed541003Pharma Surgeen2026-07-31T00:00:00.000ZTherapeutic Potential of Talahridaya Marma in Cardiovascular Homeostasis: A Clinical Reviewhttps://www.pharmaradar360.com/article/medilink-a-secure-role-based-healthcare-management-platform-with-integrated-rule-d5a9af8aff75273cPharma Surgeen2026-07-31T00:00:00.000ZMediLink: A Secure Role-Based Healthcare Management Platform with Integrated Rule-Based Clinical Decision Support and Multilingual Voice Interactionhttps://www.pharmaradar360.com/article/cross-modal-deep-learning-framework-for-multi-disease-risk-assessment-using-clin-2ceb7f72c8ec3244Pharma Surgeen2026-07-31T00:00:00.000ZCross-Modal Deep Learning Framework for Multi-Disease Risk Assessment Using Clinical Data and Medical Imageshttps://www.pharmaradar360.com/article/clinical-text-mining-with-bert-for-lung-cancer-prognosis-a-comparative-survival-d102bca8fa735123Pharma Surgeen2026-07-31T00:00:00.000ZClinical Text Mining with BERT for Lung Cancer Prognosis: A Comparative Survival Analysishttps://www.pharmaradar360.com/article/prevalence-associated-factors-and-clinical-outcomes-of-atrial-fibrillation-among-ace139ba463a647cPharma Surgeen2026-07-31T00:00:00.000ZPrevalence, associated factors and clinical outcomes of atrial fibrillation among acute stroke patients in Mwanza, Tanzania. A cross-section studyhttps://www.pharmaradar360.com/article/video-based-markerless-motion-capture-for-clinical-and-rehabilitation-biomechani-78ddee2082259807Pharma Surgeen2026-07-31T00:00:00.000ZVideo-Based Markerless Motion Capture for Clinical and Rehabilitation Biomechanics: A PRISMA-ScR Scoping Review of Validated Architectures, Clinical Readiness, and Emerging Methodshttps://www.pharmaradar360.com/article/use-of-a-vessel-sealing-device-during-elective-orchiectomy-in-client-owned-pet-r-05428d6ca2abd742Pharma Surgeen2026-07-31T00:00:00.000ZUse of a Vessel Sealing Device During Elective Orchiectomy in Client-Owned Pet Rabbits: A Clinical Comparison with Conventional Ligationhttps://www.pharmaradar360.com/article/machine-learning-prediction-of-postoperative-pain-improvement-following-coronary-74ed49f40817d6b2Pharma Surgeen2026-07-31T00:00:00.000ZMachine Learning Prediction of Postoperative Pain Improvement Following Coronary Artery Bypass Grafting Using Preoperative Clinical, Psychosocial, Fatigue, and Functional Variableshttps://www.pharmaradar360.com/article/a-psychoanalytic-inquiry-into-the-pastoral-counselor-s-good-shepherd-complex-foc-1eee533b4f841b3cPharma Surgeen2026-07-31T00:00:00.000ZA Psychoanalytic Inquiry into the Pastoral Counselor’s ‘Good Shepherd Complex’ — Focusing on the Reconfiguration of the Counselor’s Goodwill and Clinical Responsibilityhttps://www.pharmaradar360.com/article/rhinoconjunctivitis-and-probable-bronchial-asthma-due-to-sensitization-to-transg-ba80da1a35f801c4Pharma Surgeen2026-07-31T00:00:00.000ZRhinoconjunctivitis and Probable Bronchial Asthma Due to Sensitization to Transglutaminasehttps://www.pharmaradar360.com/article/nutritional-support-for-critically-ill-patients-by-the-korean-society-for-parent-04104f5d1ff12cfdPharma Surgeen2026-07-31T00:00:00.000ZNutritional support for critically ill patients by the Korean Society for Parenteral and Enteral Nutrition—part II: a clinical practice guidelinehttps://www.pharmaradar360.com/article/mechanistic-insights-clinical-significance-and-management-strategies-for-postgas-8386d5ace0962561Pharma Surgeen2026-07-31T00:00:00.000ZMechanistic insights, clinical significance, and management strategies for postgastrectomy hypoglycemia in gastric cancer patients in the era of continuous glucose monitoring: a narrative reviewhttps://www.pharmaradar360.com/article/noninvasive-brain-stimulation-for-parkinson-s-disease-therapeutic-applications-a-55032b1b1ca66c3bPharma Surgeen2026-07-31T00:00:00.000ZNoninvasive Brain Stimulation for Parkinson’s Disease: Therapeutic Applications and Clinical Perspectiveshttps://www.pharmaradar360.com/article/adoption-of-decentralized-clinical-trial-terminology-a-systematic-review-of-self-e38770ee916e8f5cPharma Surgeen2026-07-31T00:00:00.000ZAdoption of ‘decentralized’ clinical trial terminology: a systematic review of self-identified decentralized clinical trialshttps://www.pharmaradar360.com/article/clinical-profile-of-dengue-patients-presenting-with-epistaxis-at-a-tertiary-hosp-6312280f80cd5650Pharma Surgeen2026-07-31T00:00:00.000ZClinical profile of dengue patients presenting with epistaxis at a tertiary hospital in Kathmandu, Nepalhttps://www.pharmaradar360.com/article/clinical-characteristics-diagnostic-challenges-and-management-of-pulmonary-actin-2f0e19a29e56936dPharma Surgeen2026-07-31T00:00:00.000ZClinical characteristics, diagnostic challenges, and management of pulmonary actinomycosis: a 10-year retrospective cohort studyhttps://www.pharmaradar360.com/article/propofol-for-palliative-sedation-a-systematic-review-of-clinical-outcomes-safety-7eeb708a931faa0ePharma Surgeen2026-07-31T00:00:00.000ZPropofol for palliative sedation: A systematic review of clinical outcomes, safety, and ethical implicationshttps://www.pharmaradar360.com/article/tricuspid-valve-regurgitation-following-stylet-lumen-less-active-fixation-lead-o-5b9208b04daf9be6Pharma Surgeen2026-07-31T00:00:00.000ZTricuspid Valve Regurgitation Following Stylet Lumen‐Less Active Fixation Lead or Leadless Pacemaker Implantationhttps://www.pharmaradar360.com/article/patient-reported-outcome-measures-and-clinical-performance-in-hemophilia-implica-cc9bf4d8aa11f657Pharma Surgeen2026-07-31T00:00:00.000ZPatient‐Reported Outcome Measures and Clinical Performance in Hemophilia: Implications for Person‐Centered Carehttps://www.pharmaradar360.com/article/comment-on-advancing-geriatric-care-in-japan-integrating-the-scp-5ms-scp-framewo-e9a837f1e47c9022Pharma Surgeen2026-07-31T00:00:00.000ZComment on “Advancing Geriatric Care in Japan: Integrating the <scp>5Ms</scp> Framework With Comprehensive Geriatric Assessment for Enhanced Clinical Practice in a Super‐Aged Society”https://www.pharmaradar360.com/article/scp-i-cyp2c19-i-scp-c-scp-681g-scp-gt-a-is-not-in-complete-linkage-disequilibriu-d01f3623cd9e8fcaPharma Surgeen2026-07-31T00:00:00.000Z<scp> <i>CYP2C19</i> </scp> c. <scp>681G</scp> >A Is not in Complete Linkage Disequilibrium With c.332‐ <scp>23A</scp> >G: Implications for Pharmacogenetic Testinghttps://www.pharmaradar360.com/article/development-of-a-high-content-stem-cell-focused-drug-screening-platform-for-i-sc-dcb8662964a99ba0Pharma Surgeen2026-07-31T00:00:00.000ZDevelopment of a High-Content Stem Cell Focused Drug Screening Platform for <i>Schistosoma mansoni</i> Using Developmentally Advanced Liver Schistosomula - Functional Insights and New Protein Target Leadshttps://www.pharmaradar360.com/article/protection-at-the-margins-92e911c538a67d3fPharma Surgeen2026-07-31T00:00:00.000ZProtection at the Marginshttps://www.pharmaradar360.com/article/efficacy-and-evidential-quality-of-antioxidant-supplementation-in-human-sperm-pr-98f57a5b88a696e2Pharma Surgeen2026-07-31T00:00:00.000ZEfficacy and Evidential Quality of Antioxidant Supplementation in Human Sperm Processing Media: A Scoping Reviewhttps://www.pharmaradar360.com/article/from-fungicide-to-phagosome-a-one-health-view-of-copper-driven-fungal-bacterial-7e3e2a6576cc07c8Pharma Surgeen2026-07-31T00:00:00.000ZFrom Fungicide to Phagosome: A One Health View of Copper-Driven Fungal–Bacterial Interactionshttps://www.pharmaradar360.com/article/iot-xai-fusion-for-smart-and-transparent-clinical-decision-support-systems-311bbf08666530eePharma Surgeen2026-07-31T00:00:00.000ZIoT-XAI Fusion for Smart and Transparent Clinical Decision Support Systemshttps://www.pharmaradar360.com/article/influence-of-fish-skin-i-labeo-rohita-i-and-chia-seed-oil-i-salvia-hispanica-i-b-0d025d0cb6abe8dfPharma Surgeen2026-07-31T00:00:00.000ZInfluence of Fish Skin ( <i>Labeo rohita</i> ) and Chia Seed Oil ( <i>Salvia hispanica</i> ) Blend on the Protein‐Rich Breakfast Cereal Product Made Through the Use of Whole and Modified Chia Flour and Fish Skin Protein Isolateshttps://www.pharmaradar360.com/article/digital-cognitive-testing-in-mitochondrial-disease-validity-and-challenges-for-c-c24000a04d3c1e0fPharma Surgeen2026-07-31T00:00:00.000ZDigital Cognitive Testing in Mitochondrial Disease: Validity and Challenges for Clinical Trial Usehttps://www.pharmaradar360.com/article/compounding-must-not-become-a-drug-approval-shortcut-for-big-wellness-3f6b4899bf0798f0Pharma Surgeen2026-07-30T22:49:44.000ZCompounding must not become a drug-approval shortcut for Big Wellnesshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-shanghai-fudan-zhangjiang-bio-pharmaceutical-1b18458566ec38c8Pharma Surgeen2026-07-30T22:21:28.000ZEnterprise value to EBIT forward of Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class H – HKEX:1349https://www.pharmaradar360.com/article/cha-biotech-co-ltd-revenue-breakdown-krx-085660-ce2a13d2a5593233Pharma Surgeen2026-07-30T21:55:13.000ZCHA Biotech Co., Ltd. Revenue Breakdown – KRX:085660https://www.pharmaradar360.com/article/outbreak-investigation-of-e-coli-frozen-blueberries-july-2026-ce68aed69780dfb6Pharma Surgeen2026-07-30T21:33:56.000ZOutbreak Investigation of E. coli: Frozen Blueberries (July 2026)https://www.pharmaradar360.com/article/investors-purchase-high-volume-of-put-options-on-teva-pharmaceutical-industries-ffe8cd32f849fd68Pharma Surgeen2026-07-30T21:31:40.000ZInvestors Purchase High Volume of Put Options on Teva Pharmaceutical Industries (NYSE:TEVA)https://www.pharmaradar360.com/article/early-surgery-for-bacterial-eye-infection-offers-hope-to-patients-faad284124f10c5cPharma Surgeen2026-07-30T21:20:06.000ZEarly surgery for bacterial eye infection offers hope to patientshttps://www.pharmaradar360.com/article/pharma-fundamentals-hold-times-in-biopharmaceuticals-an-introduction-af712b2cfb35f27cPharma Surgeen2026-07-30T21:02:36.000ZPharma Fundamentals: Hold Times in Biopharmaceuticals, an Introductionhttps://www.pharmaradar360.com/article/federal-biotech-commission-examines-colorado-s-role-in-critical-minerals-product-73970e3e3cecd01dPharma Surgeen2026-07-30T20:58:57.000ZFederal biotech commission examines Colorado’s role in critical minerals productionhttps://www.pharmaradar360.com/article/leading-oncology-journal-accepts-for-publication-new-cel-sci-multikine-phase-3-d-2a55f5bd23697afaPharma Surgeen2026-07-30T20:39:08.000ZLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patientshttps://www.pharmaradar360.com/article/regulation-and-policy-update-for-h2-2026-779ed3f87d2df204Pharma Surgeen2026-07-30T20:28:08.000ZRegulation and policy update for H2 2026https://www.pharmaradar360.com/article/apple-tree-gets-4m-for-biotech-cos-as-managers-take-over-8aaf493a9cac8408Pharma Surgeen2026-07-30T20:20:00.000ZApple Tree Gets $4M For Biotech Cos. As Managers Take Overhttps://www.pharmaradar360.com/article/maharashtra-fda-trains-guns-on-overpriced-drugs-e66ec9d8e287b357Pharma Surgeen2026-07-30T20:12:00.000ZMaharashtra FDA trains guns on overpriced drugshttps://www.pharmaradar360.com/article/karyopharm-announces-topline-results-from-phase-3-xport-ec-042-trial-in-endometr-69c490bed3349b7cPharma Surgeen2026-07-30T20:09:15.000ZKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancerhttps://www.pharmaradar360.com/article/keros-expects-to-distribute-25-of-net-cash-proceeds-after-takeda-payment-5e411e0219ce0d67Pharma Surgeen2026-07-30T20:01:00.000ZKeros expects to distribute 25% of net cash proceeds after Takeda paymenthttps://www.pharmaradar360.com/article/euro-roundup-efpia-pushes-for-shorter-trial-approval-times-in-eu-biotech-act-7f6bc76af1407256Pharma Surgeen2026-07-30T19:28:00.000ZEuro Roundup: EFPIA pushes for shorter trial approval times in EU Biotech Acthttps://www.pharmaradar360.com/article/insilico-medicine-to-present-ai-designed-drug-for-mesothelioma-treatment-fda-to-f3b0f1abe42f9161Pharma Surgeen2026-07-30T18:35:46.000ZInsilico Medicine to Present AI-Designed Drug for Mesothelioma Treatment, FDA to Fast-Trackhttps://www.pharmaradar360.com/article/aardvark-shares-plunge-32-after-fda-halts-clin-1ee68ceb2ab7b20aPharma Surgeen2026-07-30T18:08:49.000ZAardvark shares plunge 32% after FDA halts clin...https://www.pharmaradar360.com/article/mexico-s-pharmaceutical-and-healthcare-sectors-under-scrutiny-as-regulators-zero-ba295663351bec1aPharma Surgeen2026-07-30T18:04:19.000ZMexico’s pharmaceutical and healthcare sectors under scrutiny as regulators zero in on cartel conducthttps://www.pharmaradar360.com/article/eu-regulatory-roundup-abbvie-pfizer-biontech-and-incyte-net-approvals-9556f1ba536fafe4Pharma Surgeen2026-07-30T18:00:06.000ZEU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvalshttps://www.pharmaradar360.com/article/inizio-engage-launches-connected-insights-pharmexec-17c262411d583f9dPharma Surgeen2026-07-30T17:57:09.000ZInizio Engage launches Connected Insights | PharmExechttps://www.pharmaradar360.com/article/these-2-biotech-stocks-hit-new-52-week-highs-today-and-cort-clocked-its-best-day-7dae0ef6b7ea1534Pharma Surgeen2026-07-30T17:55:16.000ZThese 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Monthshttps://www.pharmaradar360.com/article/sumitomo-pharma-america-announces-enzomenib-dsp-5336-receives-fda-orphan-drug-de-6df99115a905af7aPharma Surgeen2026-07-30T17:49:43.000ZSumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemiahttps://www.pharmaradar360.com/article/how-biotech-steadies-beauty-s-ingredient-supply-chain-challenges-9d93c60ad7674355Pharma Surgeen2026-07-30T17:47:07.000ZHow biotech steadies beauty’s ingredient supply chain challengeshttps://www.pharmaradar360.com/article/aardvark-therapeutics-aard-scrutinized-again-after-fda-hold-on-lead-drug-candida-71df8fc3c08feec9Pharma Surgeen2026-07-30T17:46:54.000ZAardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Bermanhttps://www.pharmaradar360.com/article/weekly-oral-islatravir-lenacapavir-noninferior-to-daily-hiv-therapy-in-phase-3-t-11ca98c807ba33c3Pharma Surgeen2026-07-30T17:45:36.000ZWeekly Oral Islatravir–Lenacapavir Noninferior to Daily HIV Therapy in Phase 3 Trialhttps://www.pharmaradar360.com/article/why-collaboration-is-key-in-biotech-9e77d8e115b07bebPharma Surgeen2026-07-30T17:19:39.000ZWhy Collaboration is Key in Biotechhttps://www.pharmaradar360.com/article/kelun-biotech-s-sac-tmt-gains-nmpa-review-for-first-line-advanced-tnbc-indicatio-ace16212127353fbPharma Surgeen2026-07-30T17:19:38.000ZKelun-Biotech's Sac-TMT Gains NMPA Review for First-Line Advanced TNBC Indicationhttps://www.pharmaradar360.com/article/eyepoint-stock-could-surge-over-200-as-mizuho-names-biotech-company-its-top-smal-e8848411e3828640Pharma Surgeen2026-07-30T17:06:00.000ZEyePoint stock could surge over 200% as Mizuho names biotech company its top small cap pickhttps://www.pharmaradar360.com/article/pharmaceutical-companies-in-talks-with-nice-about-access-to-alzheimer-s-drugs-c28f0012155b7025Pharma Surgeen2026-07-30T16:31:50.000ZPharmaceutical companies in talks with NICE about access to Alzheimer’s drugshttps://www.pharmaradar360.com/article/j-j-nabs-option-to-buy-in-vivo-car-t-maker-sail-for-nearly-2-6b-2e89be5c045ef321Pharma Surgeen2026-07-30T16:02:11.000ZJ&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6Bhttps://www.pharmaradar360.com/article/botulinum-toxin-wins-first-fda-clearance-to-test-frown-muscle-theory-of-depressi-5b2a6b43595d5455Pharma Surgeen2026-07-30T15:40:30.000ZBotulinum Toxin Wins First FDA Clearance to Test Frown-Muscle Theory of Depressionhttps://www.pharmaradar360.com/article/tadekinig-alfa-a051011f4703cdc6Pharma Surgeen2026-07-30T15:30:00.000ZTadekinig alfaの米国におけるオプション権行使のお知らせhttps://www.pharmaradar360.com/article/india-takes-action-against-90-of-inspected-high-risk-pharmaceutical-facilities-r-5bb5b9d28cedadacPharma Surgeen2026-07-30T15:23:45.000ZIndia takes action against 90% of inspected high-risk pharmaceutical facilities, regulator sayshttps://www.pharmaradar360.com/article/pharma-pulse-infinitus-ai-hub-play-eversana-s-cell-therapy-partnership-cold-chai-aeb20a5dac9e856ePharma Surgeen2026-07-30T15:01:14.000ZPharma Pulse: Infinitus' AI Hub Play, EVERSANA's Cell Therapy Partnership, Cold Chain Dealshttps://www.pharmaradar360.com/article/bms-ceo-boerner-doesn-t-feel-any-compulsion-to-chase-deals-despite-lack-of-m-a-t-727097ffe235dbf5Pharma Surgeen2026-07-30T14:37:08.000ZBMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearhttps://www.pharmaradar360.com/article/china-s-fermentation-giants-turn-to-mycoprotein-as-pharma-margins-shrink-5f34e9638974deb4Pharma Surgeen2026-07-30T14:32:09.000ZChina’s Fermentation Giants Turn to Mycoprotein as Pharma Margins Shrinkhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-30T14:30:09.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-30T14:30:09.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/it-s-a-peptide-wild-west-how-rfk-jr-is-clearing-way-for-a-market-of-untested-dru-46ade855ec6c0d7dPharma Surgeen2026-07-30T14:21:00.000Z‘It’s a peptide wild west’: how RFK Jr is clearing way for a market of untested drugshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-stock-12-month-price-target-raised-to-19-1-0a74a6b27292da2aPharma Surgeen2026-07-30T14:20:22.000ZTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.13, Implies 8% Upsidehttps://www.pharmaradar360.com/article/australia-approves-first-in-class-niktimvo-for-later-line-cgvhd-5876454f27c3c212Pharma Surgeen2026-07-30T14:10:53.000ZAustralia approves first-in-class Niktimvo for later-line cGVHDhttps://www.pharmaradar360.com/article/fda-adcom-shuns-capricor-s-dmd-cell-therapy-amid-data-dispute-98cd559de40f92f8Pharma Surgeen2026-07-30T14:05:53.000ZFDA AdCom shuns Capricor’s DMD cell therapy amid data disputehttps://www.pharmaradar360.com/article/health-protection-report-volume-20-2026-f9e0b8a49f9df3c3Pharma Surgeen2026-07-30T14:00:02.000ZHealth Protection Report volume 20 (2026)https://www.pharmaradar360.com/article/national-partnership-agreement-on-asylum-seeker-health-in-england-a7f2599358415303Pharma Surgeen2026-07-30T14:00:00.000ZNational partnership agreement on asylum seeker health in Englandhttps://www.pharmaradar360.com/article/greenberg-traurig-advises-entera-bio-in-record-275m-israeli-biotech-pipe-e06869d115e09589Pharma Surgeen2026-07-30T13:48:44.000ZGreenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPEhttps://www.pharmaradar360.com/article/gsk-ai-biotech-relation-pen-110m-biological-datasets-pact-adefe9e9df13bed4Pharma Surgeen2026-07-30T13:46:54.000ZGSK, AI biotech Relation pen $110M biological datasets pacthttps://www.pharmaradar360.com/article/pharmacy-inside-jobs-sports-pharmacist-9877f234993a94c7Pharma Surgeen2026-07-30T13:44:00.000ZPharmacy Inside Jobs : sports pharmacisthttps://www.pharmaradar360.com/article/recordati-publication-of-the-interim-report-first-half-as-at-30-06-2026-6a35e40675f455d6Pharma Surgeen2026-07-30T13:42:09.000ZRECORDATI: PUBLICATION OF THE INTERIM REPORT FIRST HALF (AS AT 30.06.2026)https://www.pharmaradar360.com/article/boston-scientific-cuts-guidance-again-after-unveiling-restructuring-plan-4bb3180d9a19e55bPharma Surgeen2026-07-30T13:33:27.000ZBoston Scientific cuts guidance again after unveiling restructuring planhttps://www.pharmaradar360.com/article/ember-alfresa-strike-japan-cold-chain-alliance-58ab4c595f625835Pharma Surgeen2026-07-30T13:26:14.000ZEmber, Alfresa Strike Japan Cold Chain Alliancehttps://www.pharmaradar360.com/article/regulations-are-being-implemented-fda-commissioner-tukaram-munde-on-statewide-fo-da12491db0bb9340Pharma Surgeen2026-07-30T13:21:22.000ZRegulations Are Being Implemented: FDA Commissioner Tukaram Munde On Statewide Food Safety Drive - VIDEOhttps://www.pharmaradar360.com/article/ember-lifesciences-wins-alfresa-backing-for-japan-cold-chain-push-6c165a841a5e6230Pharma Surgeen2026-07-30T13:17:50.000ZEmber LifeSciences wins Alfresa backing for Japan cold chain pushhttps://www.pharmaradar360.com/article/nhs-and-industry-join-forces-on-next-generation-of-hospitals-35ccd7191fb21b0fPharma Surgeen2026-07-30T13:13:00.000ZNHS and industry join forces on next generation of hospitalshttps://www.pharmaradar360.com/article/cingulate-publishes-phase-3-adhd-drug-trial-results-in-journal-e7c602eea1a88265Pharma Surgeen2026-07-30T13:08:09.000ZCingulate publishes phase 3 ADHD drug trial results in journalhttps://www.pharmaradar360.com/article/imunon-reports-strong-enrollment-momentum-in-phase-3-ovation-3-trial-of-imnn-001-7a9a201434fbdf9fPharma Surgeen2026-07-30T13:07:37.000ZIMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancerhttps://www.pharmaradar360.com/article/what-s-next-for-direct-to-patient-091981349bbbf0bePharma Surgeen2026-07-30T13:06:14.000ZWhat's Next for Direct-to-Patient?https://www.pharmaradar360.com/article/mhra-safety-roundup-july-2026-b94269bf7f34dce3Pharma Surgeen2026-07-30T13:03:00.000ZMHRA Safety Roundup: July 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090Pharma Surgeen2026-07-30T13:00:02.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69Pharma Surgeen2026-07-30T13:00:02.000ZNational flu and COVID-19 surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season-d6b3a2494c57cfa7Pharma Surgeen2026-07-30T13:00:02.000ZNational flu and COVID-19 surveillance reports: 2025 to 2026 seasonhttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-30T13:00:02.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-30T13:00:02.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-measles-guidelines-19fe295025dcfc04Pharma Surgeen2026-07-30T13:00:02.000ZNational measles guidelineshttps://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-30T13:00:02.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-30T13:00:02.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-30T13:00:02.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-30T13:00:02.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/attovia-braveheart-and-vogenx-seek-more-than-500m-across-trio-of-ipos-5a14db69e13a11efPharma Surgeen2026-07-30T12:57:43.000ZAttovia, Braveheart and Vogenx seek more than $500M across trio of IPOshttps://www.pharmaradar360.com/article/will-generic-drug-tariffs-impact-pharma-etfs-308818d988283d90Pharma Surgeen2026-07-30T12:53:00.000ZWill Generic Drug Tariffs Impact Pharma ETFs?https://www.pharmaradar360.com/article/hk-restates-support-for-cell-and-gene-therapy-amid-biotech-push-08393485127236baPharma Surgeen2026-07-30T12:49:42.000ZHK restates support for cell and gene therapy amid biotech pushhttps://www.pharmaradar360.com/article/cingulate-announces-publication-of-phase-3-adhd-trial-results-in-journal-of-chil-a4b26e319595bd6cPharma Surgeen2026-07-30T12:45:37.000ZCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacologyhttps://www.pharmaradar360.com/article/sellas-life-sciences-clinical-biopharmaceutical-company-0899336d73776e11Pharma Surgeen2026-07-30T12:45:02.000ZSELLAS Life Sciences - Clinical Biopharmaceutical Companyhttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-net-asset-value-s-eb15919be77b9b35Pharma Surgeen2026-07-30T12:44:00.000ZThe Biotech Growth Trust PLC - Net Asset Value(s)https://www.pharmaradar360.com/article/in-photos-sudents-in-maharashtra-may-soon-see-healthier-school-menus-b033ea854c7d902fPharma Surgeen2026-07-30T12:39:00.000ZIN PHOTOS: Sudents in Maharashtra may soon see healthier school menushttps://www.pharmaradar360.com/article/india-takes-action-against-90-pct-of-inspected-high-risk-pharmaceutical-faciliti-a544b4a7d578cc34Pharma Surgeen2026-07-30T12:38:55.000ZIndia takes action against 90 pct of inspected high-risk pharmaceutical facilitieshttps://www.pharmaradar360.com/article/leading-oncology-journal-accepts-for-publication-new-cel-sci-multikine-phase-3-d-d8205ff711bcdcc3Pharma Surgeen2026-07-30T12:31:00.000ZLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patientshttps://www.pharmaradar360.com/article/cingulate-s-adhd-candidate-improved-scores-at-all-three-doses-6dd1981e0bfc7c73Pharma Surgeen2026-07-30T12:30:00.000ZCingulate's ADHD candidate improved scores at all three doseshttps://www.pharmaradar360.com/article/mmi-receives-fda-approval-to-advance-to-phase-ii-of-patient-enrollment-in-ground-570a69cfeaabc312Pharma Surgeen2026-07-30T12:24:45.000ZMMI Receives FDA Approval to Advance to Phase II of Patient Enrollment in Groundbreaking REMIND Microsurgical Study in Alzheimer’s Patientshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-q2-earnings-call-highlights-edacb5d353369133Pharma Surgeen2026-07-30T12:22:30.000ZTeva Pharmaceutical Industries Q2 Earnings Call Highlightshttps://www.pharmaradar360.com/article/germany-apax-to-carve-out-two-market-leading-pharmaceutical-packaging-businesses-e6de6520446bce83Pharma Surgeen2026-07-30T12:13:50.000ZGermany: Apax to carve out two market-leading pharmaceutical packaging businesses from Gerresheimerhttps://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-teva-a-bargain-after-results-and-higher-revenu-3e6f9c195f430ed5Pharma Surgeen2026-07-30T12:08:17.000ZIs Teva Pharmaceutical Industries (TEVA) A Bargain After Results And Higher Revenue Guidance?https://www.pharmaradar360.com/article/bombay-hc-tells-fda-to-focus-on-serious-food-safety-violations-not-minor-infract-eb095cc998a47e04Pharma Surgeen2026-07-30T12:06:22.000ZBombay HC Tells FDA to Focus on Serious Food Safety Violations, Not Minor Infractionshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-q1-earnings-call-highlights-e91895cb129ad3f1Pharma Surgeen2026-07-30T12:03:52.000ZTakeda Pharmaceutical Q1 Earnings Call Highlightshttps://www.pharmaradar360.com/article/a16z-backed-biotech-braveheart-seeks-318-8-million-in-us-ipo-7fab0dbf1b1a1f09Pharma Surgeen2026-07-30T12:02:53.000ZA16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPOhttps://www.pharmaradar360.com/article/pharmasave-regular-strength-dairy-digestive-supplement-lactase-enzyme-affected-l-973cead0f53c0809Pharma Surgeen2026-07-30T12:00:00.000ZPharmasave Regular Strength Dairy Digestive Supplement Lactase Enzyme: Affected lot is labelled with the incorrect Natural Product Number (NPN) on the carton.https://www.pharmaradar360.com/article/femyso-affected-lot-may-contain-two-green-mifepristone-cartons-or-two-pink-misop-41bf219c489ece80Pharma Surgeen2026-07-30T12:00:00.000ZFemyso: Affected lot may contain two green Mifepristone cartons or two pink Misoprostol cartons instead of one of each.https://www.pharmaradar360.com/article/masschallenge-targets-israel-taiwan-for-biotech-medtech-accelerator-cbf5cf2bd97d609aPharma Surgeen2026-07-30T12:00:00.000ZMassChallenge targets Israel, Taiwan for biotech, medtech acceleratorhttps://www.pharmaradar360.com/article/juvederm-day-returns-to-u-s-on-august-19-42341076202d1d14Pharma Surgeen2026-07-30T12:00:00.000ZJUVÉDERM® Day Returns to U.S. on August 19https://www.pharmaradar360.com/article/calls-for-collaboration-on-medical-research-in-wales-5702457c03e31897Pharma Surgeen2026-07-30T11:51:40.000ZCalls for collaboration on medical research in Waleshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-q1-results-met-expectations-with-pipeline-launches-940fb84d4b42b771Pharma Surgeen2026-07-30T11:50:14.000ZTakeda Pharmaceutical Company: Q1 results met expectations, with pipeline launches set to drive future growthhttps://www.pharmaradar360.com/article/panda-biotech-culturewell-launch-india-s-first-hemp-yarn-supply-chain-a9d85a015e1f4c7aPharma Surgeen2026-07-30T11:47:41.000ZPanda Biotech, Culturewell launch India’s first hemp yarn supply chainhttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-buy-on-legend-biotech-stock-at-65-0fa4bd2370a724c7Pharma Surgeen2026-07-30T11:42:00.000ZH.C. Wainwright reiterates Buy on Legend Biotech stock at $65https://www.pharmaradar360.com/article/incorporacion-al-mercosur-de-la-nueva-definicion-de-contaminante-en-alimentos-2b27e6385620c842Pharma Surgeen2026-07-30T11:35:06.000ZIncorporación al MERCOSUR de la nueva definición de contaminante en alimentoshttps://www.pharmaradar360.com/article/judge-says-the-fda-never-explained-why-mifepristone-prescriber-certification-was-5b32e5ffb978080fPharma Surgeen2026-07-30T11:31:30.000ZJudge Says the FDA Never Explained Why Mifepristone Prescriber Certification Was Necessaryhttps://www.pharmaradar360.com/article/actualizacion-del-codigo-alimentario-argentino-sobre-materiales-celulosicos-en-c-434690a23356dfdfPharma Surgeen2026-07-30T11:28:52.000ZActualización del Código Alimentario Argentino sobre materiales celulósicos en contacto con alimentoshttps://www.pharmaradar360.com/article/mers-cov-self-isolating-awaiting-mers-cov-test-result-4d7d31f88904d305Pharma Surgeen2026-07-30T11:25:24.000ZMERS-CoV: self-isolating awaiting MERS-CoV test resulthttps://www.pharmaradar360.com/article/alterity-s-ath434-trial-for-rare-msa-may-enroll-200-patients-32b326c49ec08f32Pharma Surgeen2026-07-30T11:25:00.000ZAlterity’s ATH434 Trial for Rare MSA May Enroll 200 Patientshttps://www.pharmaradar360.com/article/eyepoint-completes-enrollment-of-both-pivotal-phase-3-trials-of-duravyutm-for-tr-fb79ba0be55461b9Pharma Surgeen2026-07-30T11:20:48.000ZEyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)https://www.pharmaradar360.com/article/espana-pais-pionero-en-la-union-europea-en-la-supresion-del-prospecto-en-papel-e-9a354c735ec11ff8Pharma Surgeen2026-07-30T11:17:41.000ZEspaña, país pionero en la Unión Europea en la supresión del prospecto en papel en medicamentos de ámbito hospitalariohttps://www.pharmaradar360.com/article/us-high-growth-tech-stocks-to-watch-in-july-2026-5aa3966fdc5007edPharma Surgeen2026-07-30T11:15:03.000ZUS High Growth Tech Stocks To Watch In July 2026https://www.pharmaradar360.com/article/terahertz-spectroscopy-and-machine-learning-accelerate-api-analysis-8b9b4492a18fcec4Pharma Surgeen2026-07-30T11:14:32.000ZTerahertz spectroscopy and machine learning accelerate API analysishttps://www.pharmaradar360.com/article/guidance-magnetic-resonance-imaging-equipment-in-clinical-use-safety-guidelines-3b11947531275490Pharma Surgeen2026-07-30T11:13:47.000ZGuidance: Magnetic resonance imaging equipment in clinical use: safety guidelineshttps://www.pharmaradar360.com/article/eyepoint-inc-nasdaq-eypt-finishes-phase-3-dme-enrollment-sets-2027-data-goal-3ccc455cede9f057Pharma Surgeen2026-07-30T11:05:49.000ZEyePoint, Inc. (Nasdaq: EYPT) finishes Phase 3 DME enrollment, sets 2027 data goalhttps://www.pharmaradar360.com/article/eyepoint-fills-two-retinal-disease-trials-with-over-480-patients-in-five-months-457261e505f3ae1aPharma Surgeen2026-07-30T11:00:00.000ZEyePoint fills two retinal disease trials with over 480 patients in five monthshttps://www.pharmaradar360.com/article/bristol-myers-squibb-reports-second-quarter-financial-results-for-2026-c3f223e49e5e4205Pharma Surgeen2026-07-30T10:59:00.000ZBristol Myers Squibb Reports Second Quarter Financial Results for 2026https://www.pharmaradar360.com/article/panda-biotech-culturewell-launch-india-s-first-hemp-yarn-supply-chain-90e8c55886471832Pharma Surgeen2026-07-30T10:49:40.000ZPanda Biotech, Culturewell launch India’s first hemp yarn supply chainhttps://www.pharmaradar360.com/article/india-takes-action-against-90-of-inspected-high-risk-pharmaceutical-facilities-r-b7a083b58e45a649Pharma Surgeen2026-07-30T10:46:19.000ZIndia takes action against 90% of inspected high-risk pharmaceutical facilities, regulator sayshttps://www.pharmaradar360.com/article/tri-locum-partners-lp-has-30-75-million-position-in-teva-pharmaceutical-industri-39b88b9dc6a12b90Pharma Surgeen2026-07-30T10:46:05.000ZTri Locum Partners LP Has $30.75 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/pfizer-s-litfulo-studies-showed-more-facial-and-body-repigmentation-f4bcd1c9d1a48bc5Pharma Surgeen2026-07-30T10:45:00.000ZPfizer's LITFULO studies showed more facial and body repigmentationhttps://www.pharmaradar360.com/article/j-j-wagers-on-next-cell-therapy-frontier-with-2-6bn-sail-bio-acquisition-option-7ddb46ebf70351c1Pharma Surgeen2026-07-30T10:41:15.000ZJ&J wagers on next cell therapy frontier with $2.6bn Sail Bio acquisition optionhttps://www.pharmaradar360.com/article/adcom-expected-for-uniqure-s-huntington-s-gene-therapy-chief-medical-officer-say-d69190bfbe03c1d8Pharma Surgeen2026-07-30T10:40:51.000ZAdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer sayshttps://www.pharmaradar360.com/article/the-1-2tn-untapped-pharma-opportunity-in-tropical-conservation-f1a89d87c5084007Pharma Surgeen2026-07-30T10:40:51.000ZThe $1.2tn untapped pharma opportunity in tropical conservationhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-says-unit-enters-fx-swap-and-fx-forward-contracts-with-icbc-219e8bc3d5160d70Pharma Surgeen2026-07-30T10:38:57.000ZCSPC Pharmaceutical Says Unit Enters FX Swap And FX Forward Contracts With ICBC Since June 16https://www.pharmaradar360.com/article/legionnaires-disease-national-surveillance-scheme-c6b5eec941da2352Pharma Surgeen2026-07-30T10:35:56.000ZLegionnaires' disease: national surveillance schemehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-2027-q1-results-earnings-call-presentation-f0aa4656290af3ffPharma Surgeen2026-07-30T10:34:32.000ZTakeda Pharmaceutical Company Limited 2027 Q1 - Results - Earnings Call Presentation (NYSE:TAK) 2026-07-30https://www.pharmaradar360.com/article/fda-suspends-licences-of-21-pune-food-outlets-seizes-goods-worth-rs-50-65-lakh-ffdcfe8519dba9dcPharma Surgeen2026-07-30T10:34:11.000ZFDA suspends licences of 21 Pune food outlets, seizes goods worth Rs 50.65 lakhhttps://www.pharmaradar360.com/article/families-gather-at-state-capitol-to-mark-prescribed-harm-awareness-day-6ca8a37da4acdb9aPharma Surgeen2026-07-30T10:29:30.000ZFamilies gather at state capitol to mark Prescribed Harm Awareness Dayhttps://www.pharmaradar360.com/article/in-photos-sudents-in-maharashtra-may-soon-see-healthier-school-menus-fa7c35202475ea74Pharma Surgeen2026-07-30T10:18:27.000ZIN PHOTOS: Sudents in Maharashtra may soon see healthier school menushttps://www.pharmaradar360.com/article/portage-biotech-alp-stock-trends-and-sentiment-2026-alp-30e8051ee934e3faPharma Surgeen2026-07-30T10:12:07.000ZPortage Biotech (ALP) Stock Trends and Sentiment 2026 $ALPhttps://www.pharmaradar360.com/article/when-foreign-investments-in-pharma-and-biotech-become-a-national-security-concer-f26386bda2965018Pharma Surgeen2026-07-30T10:06:55.000ZWhen Foreign Investments in Pharma and Biotech Become a National Security Concernhttps://www.pharmaradar360.com/article/alterity-therapeutics-nasdaq-athe-outlines-fda-backed-phase-3-plan-for-ath434-745447facf69e726Pharma Surgeen2026-07-30T10:05:21.000ZAlterity Therapeutics (NASDAQ: ATHE) outlines FDA-backed Phase 3 plan for ATH434https://www.pharmaradar360.com/article/takeda-pharmaceutical-nyse-tak-q1-2026-revenue-1-22t-eps-71-65-2bee652264979825Pharma Surgeen2026-07-30T10:05:10.000ZTakeda Pharmaceutical (NYSE: TAK) Q1 2026 revenue ¥1.22T, EPS ¥71.65https://www.pharmaradar360.com/article/sharp-rise-in-cyclospora-infections-linked-to-mexico-travel-6e286df30d5ba91bPharma Surgeen2026-07-30T10:00:00.000ZSharp rise in cyclospora infections linked to Mexico travelhttps://www.pharmaradar360.com/article/amneal-reports-second-quarter-2026-financial-results-af07df3365c7afc1Pharma Surgeen2026-07-30T10:00:00.000ZAmneal Reports Second Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/181-294-shares-in-teva-pharmaceutical-industries-ltd-teva-acquired-by-healthcare-d7284f5efdf23c9ePharma Surgeen2026-07-30T09:46:11.000Z181,294 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Healthcare of Ontario Pension Plan Trust Fundhttps://www.pharmaradar360.com/article/ono-pharmaceutical-partners-with-phylo-to-embed-agentic-ai-with-every-discovery-5e1561178cecd539Pharma Surgeen2026-07-30T09:32:41.000ZOno Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientisthttps://www.pharmaradar360.com/article/in-photos-sudents-in-maharashtra-may-soon-see-healthier-school-menus-7dcdc96aed7a0d00Pharma Surgeen2026-07-30T09:30:00.000ZIN PHOTOS: Sudents in Maharashtra may soon see healthier school menushttps://www.pharmaradar360.com/article/j-j-pays-sail-785m-charting-course-to-possible-in-vivo-car-t-buyout-7e8cdec0ea5682d4Pharma Surgeen2026-07-30T09:29:11.000ZJ&J pays Sail $785M, charting course to possible in vivo CAR-T buyouthttps://www.pharmaradar360.com/article/study-protecting-tropical-forests-could-save-pharmaceutical-industry-up-to-1-2tr-2a97d26f780a7f2aPharma Surgeen2026-07-30T09:20:58.000ZStudy: Protecting tropical forests could save pharmaceutical industry up to $1.2trhttps://www.pharmaradar360.com/article/mumbai-food-safety-crackdown-every-licence-suspended-since-tukaram-mundhe-took-c-6bff75affeb8d749Pharma Surgeen2026-07-30T09:20:00.000ZMumbai food safety crackdown: Every licence suspended since Tukaram Mundhe took charge as FDA chiefhttps://www.pharmaradar360.com/article/ukhsa-report-shows-2-877-excess-deaths-caused-by-may-and-june-heatwaves-87b94de79fef5d1ePharma Surgeen2026-07-30T09:08:34.000ZUKHSA report shows 2,877 excess deaths caused by May and June heatwaveshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-for-older-adults-b709407e14b34df9Pharma Surgeen2026-07-30T09:01:25.000ZRespiratory syncytial virus (RSV): vaccination for older adultshttps://www.pharmaradar360.com/article/using-the-professional-title-nurse-17092dc6e135d308Pharma Surgeen2026-07-30T09:00:05.000ZUsing the professional title ‘nurse’https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-programme-7a9417a4fdf76e56Pharma Surgeen2026-07-30T08:58:55.000ZRespiratory syncytial virus (RSV) vaccination programmehttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-anik-che-rise-with-q2-results-icui-nbix-rprx-27ccdfdd80a125b9Pharma Surgeen2026-07-30T08:53:00.000ZBiotech Stocks At 52-Week Highs - ANIK & CHE Rise With Q2 Results, ICUI, NBIX, RPRXhttps://www.pharmaradar360.com/article/maharashtra-fda-staff-allege-double-shifts-severe-work-pressure-amid-staff-short-86956cd7872be855Pharma Surgeen2026-07-30T08:39:43.000ZMaharashtra FDA Staff Allege Double Shifts, Severe Work Pressure Amid Staff Shortagehttps://www.pharmaradar360.com/article/principal-financial-group-inc-decreases-holdings-in-teva-pharmaceutical-industri-f0c7609b279ab669Pharma Surgeen2026-07-30T08:37:43.000ZPrincipal Financial Group Inc. Decreases Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-raises-revenue-guidance-is-the-15-undervalua-2edba534d77c89a2Pharma Surgeen2026-07-30T08:36:25.000ZTeva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There?https://www.pharmaradar360.com/article/some-more-notes-on-pharmaceutical-tariffs-61d63400b95246b4Pharma Surgeen2026-07-30T08:35:00.000ZSome More Notes On Pharmaceutical Tariffshttps://www.pharmaradar360.com/article/u-s-dependence-on-china-is-a-national-security-risk-bdad282a651ec92fPharma Surgeen2026-07-30T08:30:25.000ZU.S. dependence on China is a national security riskhttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-30T08:30:21.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-surveillance-reports-2026-to-2027-season-1cc078fa257f8153Pharma Surgeen2026-07-30T08:30:16.000ZNational norovirus and rotavirus surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/ukhsa-ad-hoc-statistical-publications-3cbe759f572dbfdcPharma Surgeen2026-07-30T08:30:15.000ZUKHSA ad hoc statistical publicationshttps://www.pharmaradar360.com/article/interim-heat-mortality-monitoring-report-england-may-and-june-2026-a051d1a7af9c587cPharma Surgeen2026-07-30T08:30:14.000ZInterim heat mortality monitoring report, England: May and June 2026https://www.pharmaradar360.com/article/pre-release-access-lists-tuberculosis-in-england-national-quarterly-reports-8f126ee050dac709Pharma Surgeen2026-07-30T08:30:13.000ZPre-release access lists: Tuberculosis in England national quarterly reportshttps://www.pharmaradar360.com/article/pre-release-access-list-reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surve-f8f3de78c8bebefaPharma Surgeen2026-07-30T08:30:13.000ZPre-release access list: Reports of cases of TB to UK enhanced tuberculosis surveillance systems 2000 to 2024https://www.pharmaradar360.com/article/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2026-1bfcb2c59c9cd8a7Pharma Surgeen2026-07-30T08:30:13.000ZMeasles, mumps and rubella: lab-confirmed cases in England 2026https://www.pharmaradar360.com/article/haemophilus-influenzae-lab-reports-by-age-group-and-serotype-99bef29f7847333aPharma Surgeen2026-07-30T08:30:13.000ZHaemophilus influenzae: lab reports by age group and serotypehttps://www.pharmaradar360.com/article/tuberculosis-in-england-national-quarterly-reports-8174ab5932d8ff62Pharma Surgeen2026-07-30T08:30:09.000ZTuberculosis in England: national quarterly reportshttps://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-df1cab884cded473Pharma Surgeen2026-07-30T08:30:09.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems, 2000 to 2025https://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-8d544b87c4e3a12aPharma Surgeen2026-07-30T08:30:09.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems: 2000 to 2024https://www.pharmaradar360.com/article/mycoplasma-genitalium-antimicrobial-resistance-surveillance-mars-8b728d0038ccd66fPharma Surgeen2026-07-30T08:30:09.000ZMycoplasma genitalium antimicrobial resistance surveillance (MARS)https://www.pharmaradar360.com/article/tuberculosis-tb-diagnosis-screening-management-and-data-ace9722645b7304dPharma Surgeen2026-07-30T08:30:09.000ZTuberculosis (TB): diagnosis, screening, management and datahttps://www.pharmaradar360.com/article/pertussis-immunisation-in-pregnancy-vaccine-coverage-england-d2e1f6887adda4f0Pharma Surgeen2026-07-30T08:30:08.000ZPertussis immunisation in pregnancy: vaccine coverage (England)